Shares of ARS Pharmaceuticals Inc (SPRY) surged 5.79% in after-hours trading on Wednesday, following the release of the company's first-quarter 2025 financial results that exceeded analyst expectations in key areas.
The biotechnology and medical research firm reported Q1 revenue of $7.97 million, surpassing the mean analyst estimate of $7.48 million. While the company posted a quarterly adjusted loss of 35 cents per share, it met the consensus expectation of six analysts. The reported net loss for the quarter stood at $33.94 million, slightly better than the forecasted loss of $34.6 million.
Investors appear to be encouraged by ARS Pharmaceuticals' solid cash position, with the company reporting cash and investments of $275.7 million at the end of the quarter. This strong financial footing provides the company with ample resources to fund its ongoing research and development efforts. Additionally, Wall Street maintains a bullish outlook on SPRY, with a median 12-month price target of $30.00 and a consensus "strong buy" recommendation from analysts. The positive financial results, coupled with favorable analyst sentiment, likely contributed to the stock's after-hours rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.